Journal
JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume 134, Issue 2, Pages 319-325Publisher
ELSEVIER SCIENCE INC
DOI: 10.1038/jid.2013.358
Keywords
-
Categories
Funding
- National Institutes-of Health [R01-CA125103, R01-CA160495]
- Department of Defense [W81XWH-11-1-0385]
- Dr Miriam and Sheldon G Adelson Medical Research Foundation
- National Cancer Center
- Joanna M Nicolay Melanoma Foundation
Ask authors/readers for more resources
In early 2011, we reviewed the initial success of the RAF inhibitor vemurafenib in mutant V600 BRAF melanoma patients. It was soon evident that the response to RAF inhibitor is heterogeneous and that the short-term benefits are burdened by the development of resistance. The field has progressed rapidly with the Food and Drug Administration approval of vemurafenib and the development of other RAF and MEK (mitogen-activated protein kinase/extracellular signal-regulated kinase) inhibitors. Despite these advances, the issue of RAF inhibitor resistance remains. Here, we review recent clinical advances in the field, the growing number of resistance mechanisms, preclinical evidence for combinatorial trials using RAF inhibitors as the building blocks, and the new challenges that are arising.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available